CS logo
small CS logo
Instituto de Cardiología de Corrientes

Corrientes, Argentina
Medical center in Corrientes
Bolívar 1334, W3400 CDS, Corrientes

About Instituto de Cardiología de Corrientes


"Institución de referencia en la región y en el país, líder en las prácticas asistenciales que brinda (generando salud y bienestar con sentido humano), referencia local, nacional e internacional en proyectos de investigación biomédica."
  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender
Lead Sponsor
# Trials
Boehringer Ingelheim
6
Actelion
4
Gilead Sciences
4
Bayer
3
Pfizer
3
United Therapeutics
3
Reata Pharmaceuticals, Inc.
2
Amgen
1
Eli Lilly and Company
1
Hospital Universitari Vall d'Hebron Research Institute
1
Kowa Research Institute, Inc.
1
Total Rows: 14

Clinical Trials at Instituto de Cardiología de Corrientes


During the past decade, Instituto de Cardiología de Corrientes conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 13 clinical trials were completed, i.e. on average, 72.2% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 8 clinical trials were completed. i.e. 114.3% of trials that started reached the finish line.
Created with Highcharts 11.1.0TrialsTrials Trend - Last 10 Years11115522225511111111003300333322Started TrialsCompleted Trails201520162017201820192020202120220246
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan
2003-09-01
2006-07-01
Completed
3,600
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
2007-05-01
2010-05-01
Terminated
661
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension
2006-09-01
2009-08-01
Completed
849
A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)
2004-02-01
2010-03-01
Completed
383
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
2008-05-01
2012-04-01
Completed
742
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
2008-10-17
2020-12-07
Completed
550
Study of Ambrisentan in Participants With Pulmonary Hypertension
2008-11-17
2019-09-11
Completed
140
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
2009-12-01
2014-10-01
Completed
1,156

Rows per page:

1–32 of 32

Clinical Trials Sponsors and Collaborators


Out of the total clinical trials conducted in "Instituto de Cardiología de Corrientes" #1 sponsor was "Boehringer Ingelheim" with 6 trials, followed by "Actelion" with 4 trials sponsored, "Gilead Sciences" with 4 trials sponsored, "Bayer" with 3 trials sponsored and "Pfizer" with 3 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 14 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto de Cardiología de Corrientes" #1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "Canadian VIGOUR Centre" with 1 trials as a collaborator, "Drugs for Neglected Diseases initiative" with 1 trials as a collaborator and "Duke Clinical Research Institute" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.
Created with Highcharts 11.1.0Top Leading SponsorsBoehringer Ingelheim: 6Boehringer Ingelheim: 6Actelion: 4Actelion: 4Gilead Sciences: 4Gilead Sciences: 4Bayer: 3Bayer: 3Pfizer: 3Pfizer: 3United Therapeutics: 3United Therapeutics: 3Reata Pharmaceuticals, Inc.: 2Reata Pharmaceuticals, Inc.: 2Amgen: 1Amgen: 1Eli Lilly and Company: 1Eli Lilly and Company: 1Hospital UniversitariVall d'Hebron ResearchInstitute: 1Hospital UniversitariVall d'Hebron ResearchInstitute: 1

Created with Highcharts 11.1.0Top CollaboratorsEli Lilly and Company: 4Eli Lilly and Company: 4Brigham and Women'sHospital: 1Brigham and Women'sHospital: 1Canadian VIGOUR Centre: 1Canadian VIGOUR Centre: 1Drugs for NeglectedDiseases initiative: 1Drugs for NeglectedDiseases initiative: 1Duke Clinical ResearchInstitute: 1Duke Clinical ResearchInstitute: 1ICON plc: 1ICON plc: 1Medidata Solutions: 1Medidata Solutions: 1Merck Sharp & Dohme LLC: 1Merck Sharp & Dohme LLC: 1PPD: 1PPD: 1

Clinical Trials Conditions at Instituto de Cardiología de Corrientes


According to Clinical.Site data, the most researched conditions in "Instituto de Cardiología de Corrientes" are "Pulmonary Arterial Hypertension" (8 trials), "Hypertension" (5 trials), "Pulmonary Hypertension" (5 trials), "Atrial Fibrillation" (3 trials) and "Cardiovascular Diseases" (3 trials). Many other conditions were trialed in "Instituto de Cardiología de Corrientes" in a lesser frequency.

Clinical Trials Intervention Types at Instituto de Cardiología de Corrientes


Most popular intervention types in "Instituto de Cardiología de Corrientes" are "Drug" (31 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (15 trials), "Empagliflozin" (3 trials), "Ralinepag" (3 trials), "Darusentan" (2 trials) and "Guanfacine" (2 trials). Other intervention names were less common.

Clinical Trials Genders at Instituto de Cardiología de Corrientes


The vast majority of trials in "Instituto de Cardiología de Corrientes" are 32 trials for "All" genders.

Clinical Trials Status at Instituto de Cardiología de Corrientes


Currently, there are NaN active trials in "Instituto de Cardiología de Corrientes". undefined are not yet recruiting, 4 are recruiting, 5 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 15 completed trials in Instituto de Cardiología de Corrientes, undefined suspended trials, and 6 terminated clinical trials to date.
Out of the total trials that were conducted in Instituto de Cardiología de Corrientes, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".
Created with Highcharts 11.1.0Trials By PhasePhase 3: 28Phase 3: 28Phase 2: 3Phase 2: 3

Created with Highcharts 11.1.0Trials StatusCompleted: 15Completed: 15Terminated: 6Terminated: 6Active, not recruiting: 5Active, not recruiting: 5Recruiting: 4Recruiting: 4Enrolling by invitation: 1Enrolling by invitation: 1Unknown status: 1Unknown status: 1